Movement Alert｜INNOVENT BIO Falls 3.16% in Regular Trading, Post-Earnings Profit-Taking Continues as Biotech Sector Sells Off Broadly

Market Focus08-31

On August 31, INNOVENT BIO fell 3.16% in regular trading, trading at 103.1 HKD/share, with turnover of HKD 227 million. The stock has retreated sharply from its all-time high of 112.2 HKD set on August 26, when shares surged 9.69% following a strong interim earnings release.

The company reported H1 results on August 25, with total revenue of RMB 8.618 billion, up 44.8% year-over-year, and net profit of RMB 1.253 billion, up 50.2%, with half-year profit already surpassing the full-year level of the prior year. Product revenue reached RMB 8.2 billion, up 56.7%. Multiple brokerages subsequently raised price targets, including Daiwa to 135 HKD, Morgan Stanley to 138.5 HKD, CLSA to 146.1 HKD, and Jefferies and Nomura both to 125 HKD, all maintaining buy-equivalent ratings.

Despite the favorable fundamental backdrop, the stock has faced sustained profit-taking pressure since its post-earnings peak. The broader biotechnology sector also weakened materially on the same day, with CanSinoBIO down 6.36%, Akeso down 4.72%, BeiOne Medicines down 4.81%, 3SBio down 3.30%, and Everest Medicines down 3.23%, amplifying selling pressure across the sector.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155954890?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-31 09:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155954890","market":"us","top_or_hot":-1,"title":"Movement Alert｜INNOVENT BIO Falls 3.16% in Regular Trading, Post-Earnings Profit-Taking Continues as Biotech Sector Sells Off Broadly","media":"Market Focus","content":"<p><p>On August 31, INNOVENT BIO fell 3.16% in regular trading, trading at 103.1 HKD/share, with turnover of HKD 227 million. The stock has retreated sharply from its all-time high of 112.2 HKD set on August 26, when shares surged 9.69% following a strong interim earnings release.</p><p>The company reported H1 results on August 25, with total revenue of RMB 8.618 billion, up 44.8% year-over-year, and net profit of RMB 1.253 billion, up 50.2%, with half-year profit already surpassing the full-year level of the prior year. Product revenue reached RMB 8.2 billion, up 56.7%. Multiple brokerages subsequently raised price targets, including Daiwa to 135 HKD, Morgan Stanley to 138.5 HKD, CLSA to 146.1 HKD, and Jefferies and Nomura both to 125 HKD, all maintaining buy-equivalent ratings.</p><p>Despite the favorable fundamental backdrop, the stock has faced sustained profit-taking pressure since its post-earnings peak. The broader biotechnology sector also weakened materially on the same day, with CanSinoBIO down 6.36%, Akeso down 4.72%, BeiOne Medicines down 4.81%, 3SBio down 3.30%, and Everest Medicines down 3.23%, amplifying selling pressure across the sector.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜INNOVENT BIO Falls 3.16% in Regular Trading, Post-Earnings Profit-Taking Continues as Biotech Sector Sells Off Broadly</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜INNOVENT BIO Falls 3.16% in Regular Trading, Post-Earnings Profit-Taking Continues as Biotech Sector Sells Off Broadly\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-31 09:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 31, INNOVENT BIO fell 3.16% in regular trading, trading at 103.1 HKD/share, with turnover of HKD 227 million. The stock has retreated sharply from its all-time high of 112.2 HKD set on August 26, when shares surged 9.69% following a strong interim earnings release.</p><p>The company reported H1 results on August 25, with total revenue of RMB 8.618 billion, up 44.8% year-over-year, and net profit of RMB 1.253 billion, up 50.2%, with half-year profit already surpassing the full-year level of the prior year. Product revenue reached RMB 8.2 billion, up 56.7%. Multiple brokerages subsequently raised price targets, including Daiwa to 135 HKD, Morgan Stanley to 138.5 HKD, CLSA to 146.1 HKD, and Jefferies and Nomura both to 125 HKD, all maintaining buy-equivalent ratings.</p><p>Despite the favorable fundamental backdrop, the stock has faced sustained profit-taking pressure since its post-earnings peak. The broader biotechnology sector also weakened materially on the same day, with CanSinoBIO down 6.36%, Akeso down 4.72%, BeiOne Medicines down 4.81%, 3SBio down 3.30%, and Everest Medicines down 3.23%, amplifying selling pressure across the sector.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1155954890","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155954890","pubTimestamp":1788141134,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 31, INNOVENT BIO fell 3.16% in regular trading, trading at 103.1 HKD/share, with turnover of HKD 227 million. The stock has retreated sharply from its all-time high of 112.2 HKD set on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"走势警报|信达生物常规交易下跌3.16%，生物技术板块普遍抛售，财报后获利了结仍在继续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On August 31, INNOVENT BIO fell 3.16% in regular trading, trading at 103.1 HKD/share, with turnover of HKD 227 million. The stock has retreated sharply from its all-time high of 112.2 HKD set on August 26, when shares surged 9.69% following a strong interim earnings release.The company reported H1 results on August 25, with total revenue of RMB 8.618 billion, up 44.8% year-over-year, and net profit of RMB 1.253 billion, up 50.2%, with half-year profit already surpassing the full-year level of the prior year. Product revenue reached RMB 8.2 billion, up 56.7%. Multiple brokerages subsequently raised price targets, including Daiwa to 135 HKD, Morgan Stanley to 138.5 HKD, CLSA to 146.1 HKD, and Jefferies and Nomura both to 125 HKD, all maintaining buy-equivalent ratings.Despite the favorable fundamental backdrop, the stock has faced sustained profit-taking pressure since its post-earnings peak. The broader biotechnology sector also weakened materially on the same day, with CanSinoBIO down 6.36%, Akeso down 4.72%, BeiOne Medicines down 4.81%, 3SBio down 3.30%, and Everest Medicines down 3.23%, amplifying selling pressure across the sector.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155954890","isCrawlerRequest":true}